CanSinoBIO’s Td5cp adolescent and grownup vaccine NDA accepted in China
August 19, 2026 | Wednesday | Information
China’s NMPA has accepted the brand new drug software for CanSinoBIO’s five-component tetanus, diphtheria and pertussis booster vaccine for folks aged six years and above.
CanSino Biologics has introduced that China’s Nationwide Medical Merchandise Administration has accepted the New Drug Software for its Tetanus, Lowered Diphtheria and Pertussis (Acellular, 5 Elements) Mixed Vaccine, Adsorbed, for folks aged six years and above.
The vaccine, known as Td5cp Adolescent and Grownup, is being developed as a booster for adolescents and adults and was granted Precedence Assessment standing in Could 2026.
If authorized, the vaccine is predicted to enhance CanSinoBIO’s not too long ago authorized three-component DTaP vaccine for infants, Tripecia, increasing the corporate’s pertussis-containing vaccine portfolio throughout completely different age teams.
Pertussis is a extremely contagious respiratory infectious illness brought on by Bordetella pertussis. CanSinoBIO stated reported circumstances in China exceeded 470,000 in 2024, representing an roughly 12-fold improve in contrast with 2023.
The corporate stated the resurgence has elevated consideration on booster immunisation in adolescents and adults, notably as China has lacked a devoted pertussis-containing booster vaccine for folks aged six years and above.
CanSinoBIO’s Tripecia vaccine for infants was authorized for advertising and marketing in April 2026 by means of the NMPA’s Precedence Assessment pathway.
In contrast with the three-component vaccine, which comprises PT, FHA and PRN pertussis antigens, Td5cp Adolescent and Grownup contains two extra antigens, FIM2 and FIM3.
Every antigen is individually purified and formulated at outlined ratios, with the intention of supporting product high quality and batch-to-batch consistency.
CanSinoBIO stated the continued growth of the vaccine may also help broader exploration of component-based pertussis vaccine know-how throughout completely different age teams.
In July 2026, seven Chinese language authorities departments, together with the Nationwide Illness Management and Prevention Administration and the Nationwide Growth and Reform Fee, issued the “fifteenth 5-12 months Plan for Illness Prevention and Management”, which requires a life-course immunisation technique overlaying the whole inhabitants.
The corporate stated approval of Td5cp Adolescent and Grownup would additional broaden its pertussis vaccine portfolio and help its technique of creating vaccine merchandise throughout completely different levels of life.
The NDA acceptance strikes the candidate into formal regulatory evaluate and represents the following step in direction of potential commercialisation in China.
